Join
Live feed
·
PRReleasevia Quantisnow
Provention Bio Inc. logo

Provention Bio Resubmitting Biologics License Application for Delay of Clinical Type 1 Diabetes in At-Risk Individuals Following Type B Meeting with the FDA

ByQuantisnow·Wall Street's wire, on your screen.
PRVB· Provention Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PRVB (Provention Bio Inc.) and more on Quantisnow.